Covid 19 Research using Clinical Trials (Home Page)
BMS-986253Wiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of participants infected with COVID-19. This is the first in-human study of this investigational product specifically in patients with severe COVID-19. Currently there are no FDA approved medications that improve the chance of survival in patients diagnosed with COVID-19. However there are usual treatments currently being used to help treat COVID-19 patients and BMS-986253 will be compared to these standard of care treatments in this study.
NCT04347226 Solid Tumor Sars-CoV2 Hematological Malignancy Drug: BMS-986253 MeSH:Hematologic Neoplasms
HPO:Hematological neoplasm Leukemia
Primary Outcomes
Description: The time to improvement in the 7-point ordinal scale in patients treated with anti-IL-8 therapy compared to standard of care/controls. Measured from baseline to 2 point or greater improvement in 7-point ordinal scale.
Measure: Time to Improvement in the 7-point ordinal scale Time: 1 year
Secondary Outcomes
Description: The time to death will be defined as the time from onset from symptoms until death from any cause. Patients who are alive or lost to follow-up at the cut-off date will be censored from this analysis.
Measure: Time to Death Time: 1 year
Description: The time to intubation will be defined as the time from symptom onset until time of intubation. Any patients already intubated at enrollment will be censored from this analysis.
Measure: Time to Intubation Time: 1 year
Description: The proportion of patients requiring intensive care unit (ICU) admission will be calculated as the number of patients requiring ICU admission over the course of their hospitalization over the number of evaluable patients.
Measure: Proportion of patients requiring ICU admission Time: 1 year
Description: Percentage of participants who have died 1 month from the time of start of treatment
Measure: Percentage Rate of Mortality at 1 month Time: 1 month
Related HPO nodes (Using clinical trials)
HP:0004377: Hematological neoplasm
Genes 349
ATM LIG4 KIT NF1 MPL RPL35A RPL18 DDX41 BCL10 SBDS LPP BIRC3 ETV6 F13A1 MS4A1 TP63 ATRX LIG4 JAK2 NUP214 NFKB2 FANCD2 JAK2 SF3B1 PIGL NRAS TCIRG1 RFWD3 TET2 ATRX TREX1 NTHL1 PTPN11 CALR GINS1 WIPF1 SF3B1 NOP10 RASGRP1 GATA2 GLI1 TNFRSF1B XRCC4 PRKCD NHP2 PIGA CBL MPL MPL PIGL THPO FANCG CASP10 TERC ERCC4 FANCI GATA2 CDKN2A NPM1 CBL ERBB3 PTPN11 PARN GFI1 NBN HSPA9 TET2 KIT GFI1B MAD2L2 BCR DYNC2LI1 ICOS TNFSF12 CHEK2 ELANE RPS14 FANCF USB1 RPL15 TINF2 SBDS NRAS RPL26 ADA2 RPS7 TYROBP MSH2 BCR MLH1 FANCA SLX4 CASP10 TET2 TERT TRIP13 MYD88 NUTM1 GNB1 TNFRSF13B MYC TP53 DNMT3A MDM2 SAMD9L BCL10 POT1 RPS10 EP300 BUB1B DNAJC21 CALR LIG4 BCL2 TET2 JAK2 SAMD9 SMPD1 PALB2 BUB3 PRSS1 NPM1 KIF11 ITK BCR MSH2 TAL2 SRP54 IFIH1 ABL1 FANCE RAD54B FANCM RFWD3 MLLT10 RAF1 BRAF LIG4 CBFB BLM THPO AAGAB CALR CALR TNFRSF1B NBN JAK2 TNFRSF13C DNASE1L3 RPL31 FANCG IL2RG MLF1 PIK3CA DNAJC21 CTLA4 CD28 PNP RUNX1 SETBP1 HAX1 POLE RPS26 CR2 ADA RPS27 ZAP70 ABL1 NBN KRAS RPS15A NAGS CD19 RPL11 IGH FOXP1 BUB1B RAG1 DNMT3A MSH6 FANCA TERC BUB1 FLT3 TAL1 RECQL4 PDGFRA SRP54 RPS29 MCM4 FANCE CTC1 GBA LYST STS SH3GL1 CD70 MPL FANCB SH2B3 EFL1 MAGT1 RAD51 TNFRSF13B IGH TREM2 RMRP RUNX1 FANCD2 CTLA4 DCLRE1C FAS ICOS NSD1 BRD4 RNF43 NSUN2 XIAP IL7R SH2B3 RARA BCL6 GATA2 SRP72 ATM CHIC2 IL2RG BRCA1 RTEL1 TERT ARHGAP26 TNFRSF13C TCF4 EVC SCN10A GATA1 RNASEH2B CCND1 SH2B3 XRCC2 CD19 CR2 JAK2 RPS19 MPL BRCA2 RPL27 F13B WAS TERC BCL10 TP53 COL14A1 PRKCD RPS24 TERT NUMA1 NUP214 RPL5 SH2D1A CCND1 TET2 MSH6 CFTR CD27 PGM3 FANCC EVC2 CEBPA BRCA2 TCF4 CHD7 SCN9A IGH FANCL ADAR BLM ASXL1 HLA-DRB1 RPS14 RNASEH2C SCN11A SMARCD2 GATA2 RPL35 WRAP53 TET2 PDGFRB KRAS RNASEH2A TET2 TINF2 SRP54 DNAJC21 FAS DKC1 RUNX1 APC LIG4 CD81 RECQL4 CD28 DKC1 NBEAL2 RAG2 MLH1 RPS19 ELANE SAMD9L NFKB1 PMS2 ASXL1 FANCC TSR2 PRF1 PTEN MALT1 RAD54L BRIP1 GFI1 SRSF2 TNFSF12 STAT3 ADA RPS17 FLT3 FASLG PIK3R1 KRAS CEP57 PICALM CREBBP GATA2 TP53 CTRC MYD88 TET2 RPS28 RAD51C RB1 UBE2T RMRP SPINK1 TERT KLHDC8B GATA1 JAK2 SAMHD1 RHOH Protein Mutations 0
SNP 0
HP:0001909: Leukemia
Genes 190
ATM KRAS KIT RPS15A NF1 MPL RPL35A RPL11 RPL18 DDX41 SBDS LPP ETV6 BUB1B F13A1 DNMT3A JAK2 NUP214 FANCD2 MSH6 FANCA PIGL NRAS TCIRG1 BUB1 TET2 FLT3 TAL1 ATRX TREX1 PDGFRA SRP54 RPS29 PTPN11 CALR FANCE WIPF1 SF3B1 GATA2 GLI1 STS SH3GL1 XRCC4 MPL SH2B3 EFL1 PIGA TREM2 CBL MPL RUNX1 MPL PIGL THPO FANCG NSD1 BRD4 NSUN2 SH2B3 RARA GATA2 NPM1 CBL CHIC2 ERBB3 GFI1 TERT KIT BCR ARHGAP26 DYNC2LI1 EVC SCN10A GATA1 ELANE RNASEH2B RPS14 SH2B3 JAK2 RPL15 SBDS NRAS RPL26 RPL27 ADA2 RPS7 TYROBP F13B MSH2 BCR WAS TERC TP53 TRIP13 MYD88 NUTM1 RPS24 GNB1 TP53 DNMT3A TERT NUMA1 NUP214 RPL5 SAMD9L TET2 CFTR POT1 FANCC RPS10 EP300 EVC2 BUB1B CEBPA BRCA2 DNAJC21 CALR SCN9A LIG4 ADAR BLM TET2 JAK2 SMPD1 RNASEH2C SCN11A GATA2 BUB3 PRSS1 KIF11 BCR RPL35 TAL2 SRP54 IFIH1 ABL1 PDGFRB KRAS RNASEH2A TET2 MLLT10 SRP54 DNAJC21 DKC1 RUNX1 APC LIG4 CBFB BLM THPO CALR NBN JAK2 MLH1 RPS19 ELANE SAMD9L RPL31 PMS2 ASXL1 TSR2 MLF1 PIK3CA DNAJC21 RUNX1 GFI1 SRSF2 SETBP1 HAX1 RPS26 RPS17 FLT3 RPS27 PIK3R1 KRAS CEP57 PICALM CREBBP GATA2 CTRC MYD88 TET2 RPS28 ABL1 RB1 SPINK1 GATA1 NBN JAK2 SAMHD1 Protein Mutations 51
C282Y C481S D816V D835Y E255K E255V F317C F317L F317S F317V F31I F359C F359V G250E G71R H369P H63D L248R L248V N682S P140K P1446A P4503A Q12H Q252H R132C R132G R132H R132L R132S R132V R140L R140Q R140W R172G R172K R172M R172S R172W S1612C S9333A T315A T315I T351I V158M V299L V57I V600E V617F V66M Y253H
Primary Outcomes
Description: The time to improvement in the 7-point ordinal scale in patients treated with anti-IL-8 therapy compared to standard of care/controls. Measured from baseline to 2 point or greater improvement in 7-point ordinal scale.
Measure: Time to Improvement in the 7-point ordinal scale Time: 1 yearSecondary Outcomes
Description: The time to death will be defined as the time from onset from symptoms until death from any cause. Patients who are alive or lost to follow-up at the cut-off date will be censored from this analysis.
Measure: Time to Death Time: 1 yearDescription: The time to intubation will be defined as the time from symptom onset until time of intubation. Any patients already intubated at enrollment will be censored from this analysis.
Measure: Time to Intubation Time: 1 yearDescription: The proportion of patients requiring intensive care unit (ICU) admission will be calculated as the number of patients requiring ICU admission over the course of their hospitalization over the number of evaluable patients.
Measure: Proportion of patients requiring ICU admission Time: 1 yearDescription: Percentage of participants who have died 1 month from the time of start of treatment
Measure: Percentage Rate of Mortality at 1 month Time: 1 month